Victorian Cancer Bioinformatics Symposium 2021
Friday 8th October 2021


9:30 AM Welcome and introduction

Session 1 (Chairs: Daniel Cameron, Sepideh Foroutan)

09:35 Claudia Kleinman* (McGill University, Canada) Cell of origin dependencies in pediatric brain tumors
10:20 Puxue Qiao (St. Vincent's Institute) A Bayesian model for inferring intra-tumoral heterogeneity in single cell RNA-seq
10:35 Alejandro Casar (University of Melbourne) Investigating how transcriptional plasticity drives drug resistance in cancer by combining computational modelling with single cell genomics

10:50 Morning Break

Session 2 (Chairs: Nadia Davidson, Claire Sun)

11:20 Marie Wong (Children's Cancer Institute) Graphene: Fast, flexible, affordable cancer WGS analysis on demand
11:35 Abbas Salavaty (Monash University) Identification, classification, and prioritization of the most influential players in cancer progression
11:50 Kym Berchtenbreiter* (consumer representative) Advocating for improved health outcomes: A consumer perspective
12:05 Katya Gray (WEHI) Relationships, the key to a successful Consumer partnership
12:10 Plain english videos

12:30 Poster session / Lunch Break

Session 3 (Chairs: David Goode, Ramyar Molania)

14:00 Rebecca Poulos* (University of Sydney) Molecular insights from large-scale proteomics in cancer
14:45 Raghad Al-Jarf (University of Melbourne) pdCSM-cancer: Using Graph-Based Signatures to Identify Small Molecules with Anticancer Properties
15:00 Dharmesh D Bhuva (WEHI) vissE – Visualising higher-order biological processes in cancer ‘omics datasets
15:15 Kaitao Lai (University of Sydney) Differences in microbial communities associated with geographic disparities in aggressive prostate cancer

15:30 Afternoon Break

Session 4 (Chairs: Melissa Davis, ​​Nick Wong)

16:00 Geoff Macintyre* (CNIO, Spain) A pan-cancer compendium of chromosomal instability
16:45 Nadia Davidson (PMCC) JAFFAL: Detecting fusion genes with long read transcriptome sequencing
17:00 Matthew J Wakefield (WEHI) Testing all possible mutations in PARP1 to prospectively identify resistance mutations and drug substitutions that will overcome resistance

17:15 Closing remarks

* Keynote speaker